China Aoxing Pharmaceutical Company to Present at Two Institutional Conferences in the US in May 2009
08 May 2009 - 10:00PM
Marketwired
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China
Aoxing" or the "Company"), a pharmaceutical company specializing in
research, development, manufacturing and distribution of narcotic
and pain-management products, today announced the Company's
participation in the following conferences:
-- Oppenheimer 3rd Annual China Dragon Call Conference, held May 19-21 at
300 Madison Avenue in New York City. Management is currently scheduled to
meet with institutional investors and to present from 11:25 am to 11:55 am
(EDT) on May 19;
-- JMP 8th Annual Research Conference, held May 18-20, 2009 at the Ritz-
Carlton in San Francisco. Management is currently scheduled to meet with
institutional investors and to present at 10:30 am to 11:00 am (Pacific
Time) on May 20.
For further details, please contact your institutional sales
representative.
About China Aoxing Pharmaceutical Company, Inc.
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a
pharmaceutical company located in China specializing in research,
development, manufacturing and distribution of a variety of
narcotics and pain-management products. It has a strategic alliance
with American Oriental Bioengineering, Inc. (NYSE: AOB) to develop
and market various narcotic drugs in China. Headquartered in
Shijiazhuang City, the pharmaceutical capital of China, outside of
Beijing, China Aoxing has China's largest and the most advanced
manufacturing facility for highly regulated narcotic medicines,
addressing a very under-served and fast-growing market in China.
Its facility is one of the few GMP facilities licensed for
narcotics medicines. The Company is working closely with the
Chinese government and SFDA to assure the strictly regulated
availability to medical professionals of its narcotic drugs and
pain medicines throughout China.
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks and
uncertainties that may cause actual results to differ materially
from those set forth in these statements. The economic,
competitive, governmental, technological and other risk factors
identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-KSB for the year ended
June 30, 2008, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
Contact: Wei Zhang Investor Relations China Aoxing
Pharmaceutical Company, Inc Email: chinaaoxing@gmail.com Telephone:
646 - 512 - 5662
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024